CMT On The Cloud

by | Dec 27, 2018 | 0 comments

genesis project

HNF takes Action and Joins Genomics Revolution for CMT and Rare Forms of IN

Lori and Stephan

Stephan Züchner, Founder of The Genesis Project, a cloud-based database designed for storing and analyzing genomic data, joins HNF’s TRIAD Gene Therapy Research Initiative. Also pictured Lori Sames.

“The partnership with HNF is a big step towards our mission of providing advanced genetics to even more CMT patients, ultimately guiding the way to new therapies.” – Dr. Stephen Züchner, MD, PhD Professor for Human Genetics and Neurology Chair, Dr. John T. Macdonald Foundation Department of Human Genetics Co-Director, John P. Hussman Institute for Human Genomics University of Miami Miller School of Medicine and founder of The Genesis Project

“I love what I do and I’m eager to apply what I’ve learned to other debilitating forms of inherited neuropathies. The technologies exist to treat many of these horrific disorders, but what’s absent is the attention and funding.” – Lori Sames Co-Founder of Hannah’s Hope Fund for Giant Axonal Neuropathy

“Fighter Mom” Lori Sames joins the Genesis Project, too! Lori from her kitchen table lead the development of the first-in-human gene therapy to the spinal cord, with Steven Gray, PhD UT Southwestern, as the principal investigator. Lori was able to translate to human trials in a fraction of time it typically takes industry.

A brighter future with more treatments and cures for all types of CMT.  

  • The Genesis Project collects, stores and analyzes patient registry, GRIN, CMT genomic data through their ongoing research study. This will empower GRIN to become the data hub of choice for clinical trials in CMT  
  • Support for patients that have not obtained a definitive diagnosis through genetic testing and for those interested in having personal Whole Genome Sequencing
  • Gain more insight into the genes and experience of different symptoms and onsets associated with genomics and functionality
  • Identify more secondary genes that may be CMT disease causing and modify the onset and severity of symptoms in families
  • GRIN data will be made available to CMT stakeholders
  • This is an opportunity for the best scientists globally to participate in solving the genetic diagnostic riddles of CMT and work towards therapies


GRIN connects with The Genesis Platform to accelerate a better understanding of patient’s genomics to advance gene therapy research and for recruitment in clinical trials.

Learn more on this topic

Related Blog Posts

A New Mouse Model for Charcot-Marie-Tooth (CMT2)

We were recently informed that The Jackson Laboratory (JAX, a nonprofit biomedical research institution headquartered in Bar Harbor, Maine) had taken delivery and will be distributing a newly generated CMT-related mouse model. The new model expresses mutant mitofusin 2, a mitochondrial membrane protein involved in mitochondrial fusion and regulation of vascular smooth muscle cell proliferation.

Hot Off the Press – Potential Treatment for CMT1A

Two recent publications from Pharnext describe a novel synergistic combination of 3 drugs (baclofen, naltrexone and sorbitol) and its effect on CMT1A both in the lab and in a phase II clinical trial. These 3 drugs already approved but for unrelated conditions, are combined at new optimal lower doses and under a new formulation. This novel potential therapeutic is called PXT-3003.

Support CMT Therapeutic Alliance

HNF has entered into a joint venture – the CMT Therapeutic Alliance – with a unique non profit organization (BioPontis Alliance for Rare Diseases) that brings professional drug discovery capabilities to translate our research results into potential treatments.

Sneak Peak of Fall Newsletter: CMT Research Study Survey

My name is Elizabeth Francisco and I am a graduate student from the Genetic Counseling program at the University of North Carolina Greensboro. I am inviting you to participate in a research study. The goal of my study is to learn more about the experiences of people with Charcot-Marie-Tooth (CMT) with genetic counseling and genetic testing. Adults with CMT and parents or legal guardians of someone of any age who has a diagnosis of CMT are eligible to participate

Building Awareness on CMT and Supporting the Patient Community – HNF Announces Support from Pharnext

HNFpharnext recently entered into a partnership with the French biopharmaceutical company, Pharnext, to help raise awareness of Charcot-Marie-Tooth (CMT) disease and support the CMT patient community through several initiatives. Building awareness is key! Pharnext’s support will assist HNF in distributing HNF’s CMT Update quarterly newsletter, enhancing the Global Registry for Inherited Neuropathies (GRIN), setting up activities for CMT September Awareness Month in the US and strengthening the CMT Inspire Community.

Quality of Life and CMT Research

Did you know that 95% of clinical trials fail? There are multiple causes, most related to efficacy or safety, which obviously can be harmful and risky for patients. The risk-reward of enrolling in trials is a judgment call based on the devastating effects of disease related to quality of life (QoL) or life-threatening disease. With CMT, the risk-reward is more of a challenging question for many, as CMT in most cases is non-fatal.

Help us answer questions that your doctors and the CMT Research Community aren’t too sure about.

Did you know that you can become part of a community in therapy development and further research for all forms of CMT and inherited neuropathies? The mission of the Global Registry for Inherited neuropathies (GRIN) is to collect clinical and genetic information from patients with ALL forms of Charcot-Marie-Tooth (CMT) and other related rare and ultra rare inherited neuropathies.

Hot off the press

It seems like almost weekly there is another new publication on CMT with interesting basic biology. While an earlier “Hot off the press” highlighted the work of Cherry and co-workers at the University of Texas Southwestern Medical Center who showed show that neurons lacking a gene for rab7 result in neuropathy.

Join the conversation

Leave a Comment


Submit a Comment

Your email address will not be published. Required fields are marked *


Join for notifications on events, campaigns, & news